Baidu
map

研究绘制自闭症蛋白相互作用图

2011-06-15 MedSci原创 MedSci原创

一项新的研究显示,自闭症患者脑中的分子通路与脆性X综合症、安格曼综合症及瑞特综合征等相关疾病密切相关而且共有某些关键性的蛋白质。这些发现也许能够作为发现更多的自闭症基因的一个平台。典型的自闭症是以三个主要的特点作为特征的:语言及沟通能力的丧失、社交行为能力受损及重复性的动作。在相关的或称症候群性的自闭症中,这些特征是一个大得多的症状组群的一部份。症候群性自闭症常常可被追溯至一个单一的基因,但研究人

一项新的研究显示,自闭症患者脑中的分子通路与脆性X综合症、安格曼综合症及瑞特综合征等相关疾病密切相关而且共有某些关键性的蛋白质。这些发现也许能够作为发现更多的自闭症基因的一个平台。典型的自闭症是以三个主要的特点作为特征的:语言及沟通能力的丧失、社交行为能力受损及重复性的动作。在相关的或称症候群性的自闭症中,这些特征是一个大得多的症状组群的一部份。症候群性自闭症常常可被追溯至一个单一的基因,但研究人员一直难以查明经典自闭症的遗传学基础。
 
为了找到作为经典自闭症和症候群性自闭症共同基础的共有的分子通路,Huda Zogbhi及其同事应用编码人类蛋白质的DNA序列库绘制了数千个蛋白-蛋白间的相互作用图。用已知的自闭症相关性蛋白作为钓饵,研究人员在DNA库中进行垂钓以吸引其伙伴蛋白。他们发现了大约500种与自闭症相关性蛋白有相互作用的蛋白质。换言之,研究人员显示,所有自身与自闭症有关联的蛋白都会通过共有伙伴蛋白而以某种方式联系在一起。该研究团队的蛋白-蛋白相互作用图凸显了非常紧密地连接的蛋白质;例如那些已知的在脆性X综合症中发生突变的蛋白。他们的相互作用图还显示,2种与经典自闭症相关的蛋白(SHANK3 和 TSC1)会发生相互作用并共有21个共同的伙伴蛋白。这一新的作用图是朝着揭示可作为药物标靶以治疗数种不同形式自闭症的通路所迈出的早期的一步。(来源:EurekAlert!中文版)

MedSci推荐原文出处

Science Translational Medicine  DOI: 10.1126/scitranslmed.3002166


Protein Interactome Reveals Converging Molecular Pathways Among Autism Disorders

Sakai, Yasunari; Shaw, Chad A.; Dawson, Brian C.; Dugas, Diana V.; Al-Mohtaseb, Zaina; Hill, David E.; Zoghbi, Huda Y.


To uncover shared pathogenic mechanisms among the highly heterogeneous autism spectrum disorders (ASDs), we developed a proteininteraction network that identified hundreds of new interactions among proteins encoded by ASD-associated genes. We discoveredunexpectedly high connectivity between SHANK and TSC1, previously implicated in syndromic autism, suggesting that common molecularpathways underlie autistic phenotypes in distinct syndromes. ASD patients were more likely to harbor copy number variationsthat encompass network genes than were control subjects. We also identified, in patients with idiopathic ASD, three de novolesions (deletions in 16q23.3 and 15q22 and one duplication in Xq28) that involve three network genes (NECAB2, PKM2, and FLNA). The protein interaction network thus provides a framework for identifying causes of idiopathic autism and for understandingmolecular pathways that underpin both syndromic and idiopathic ASDs.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1909163, encodeId=e4ce190916332, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Thu Sep 15 01:45:00 CST 2011, time=2011-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471483, encodeId=67f014e1483fb, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Fri Jun 17 08:45:00 CST 2011, time=2011-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527509, encodeId=6c3e152e509fa, content=<a href='/topic/show?id=68b5863e5d2' target=_blank style='color:#2F92EE;'>#自闭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86375, encryptionId=68b5863e5d2, topicName=自闭)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=159511872623, createdName=xiongke014, createdTime=Fri Jun 17 08:45:00 CST 2011, time=2011-06-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1909163, encodeId=e4ce190916332, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Thu Sep 15 01:45:00 CST 2011, time=2011-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471483, encodeId=67f014e1483fb, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Fri Jun 17 08:45:00 CST 2011, time=2011-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527509, encodeId=6c3e152e509fa, content=<a href='/topic/show?id=68b5863e5d2' target=_blank style='color:#2F92EE;'>#自闭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86375, encryptionId=68b5863e5d2, topicName=自闭)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=159511872623, createdName=xiongke014, createdTime=Fri Jun 17 08:45:00 CST 2011, time=2011-06-17, status=1, ipAttribution=)]
    2011-06-17 ylz8405
  3. [GetPortalCommentsPageByObjectIdResponse(id=1909163, encodeId=e4ce190916332, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Thu Sep 15 01:45:00 CST 2011, time=2011-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471483, encodeId=67f014e1483fb, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Fri Jun 17 08:45:00 CST 2011, time=2011-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527509, encodeId=6c3e152e509fa, content=<a href='/topic/show?id=68b5863e5d2' target=_blank style='color:#2F92EE;'>#自闭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86375, encryptionId=68b5863e5d2, topicName=自闭)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=159511872623, createdName=xiongke014, createdTime=Fri Jun 17 08:45:00 CST 2011, time=2011-06-17, status=1, ipAttribution=)]
    2011-06-17 xiongke014
Baidu
map
Baidu
map
Baidu
map